Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Wino115on Jan 25, 2023 4:36pm
210 Views
Post# 35246316

RE:Bargain hunters

RE:Bargain hunters While we are all stilted and jaded shareholders, for someone new it's not hard to see how the plan for cutting costs to get to EBITDA breakeven now and then profitable (only way they'll start to pay off loan in 2-3 years time; so have to do it) should see it far closer to the $2, then $3 just on industry comp multiples and solid revenue/earnings growth. They're in it for that 2-3x return, or even half that if they execute properly. Doesn't even require NASH, TH1902 or anything else --just big cuts and solid rev growth. Let's see in Feb when they discuss their financial and strategic goals they put in the presentation in far more detail. The financial plan will be more important now and maybe they'll have something to add around pipeline, but that may still take more delving into the numbers or talks.



<< Previous
Bullboard Posts
Next >>